Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Illidge

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
BMC Cancer|November 25, 2021
The effect of hypoxia on PD-L1 expression in bladder cancerVicky Smith, Debayan Mukherjee, Sapna Lunj, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology GroupJoachim Yahalom, Tim Illidge, Lena Specht, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 14, 2011
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trialLisa Lowry, Paul Smith, Wendi Qian, et al.
British Journal of Haematology|May 20, 2016
Guidelines for the management of diffuse large B-cell lymphomaSridhar Chaganti, Tim Illidge, Sally Barrington, et al.
European Journal of Haematology|September 27, 2017
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective studyPaul J Bröckelmann, Erin A Zagadailov, Shelby L Corman, et al.
Leukemia & Lymphoma|April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantSally Arai, Michelle Fanale, Sven DeVos, et al.
Leukemia & Lymphoma|October 19, 2017
Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and GermanyErin A Zagadailov, Shelby Corman, Viktor Chirikov, et al.
British Journal of Haematology|October 15, 2013
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphomaGraham P Collins, Anne N Parker, Christopher Pocock, et al.
British Journal of Haematology|November 23, 2021
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology GuidelineChristopher P Fox, Matthew J Ahearne, Ruth Pettengell, et al.
British Journal of Haematology|January 4, 2012
Guidelines on the investigation and management of follicular lymphomaChristopher McNamara, John Davies, Martin Dyer, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
BMC Cancer|November 25, 2021
The effect of hypoxia on PD-L1 expression in bladder cancerVicky Smith, Debayan Mukherjee, Sapna Lunj, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology GroupJoachim Yahalom, Tim Illidge, Lena Specht, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 14, 2011
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trialLisa Lowry, Paul Smith, Wendi Qian, et al.
British Journal of Haematology|May 20, 2016
Guidelines for the management of diffuse large B-cell lymphomaSridhar Chaganti, Tim Illidge, Sally Barrington, et al.
European Journal of Haematology|September 27, 2017
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective studyPaul J Bröckelmann, Erin A Zagadailov, Shelby L Corman, et al.
Leukemia & Lymphoma|April 27, 2013
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantSally Arai, Michelle Fanale, Sven DeVos, et al.
Leukemia & Lymphoma|October 19, 2017
Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and GermanyErin A Zagadailov, Shelby Corman, Viktor Chirikov, et al.
British Journal of Haematology|October 15, 2013
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphomaGraham P Collins, Anne N Parker, Christopher Pocock, et al.
British Journal of Haematology|November 23, 2021
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology GuidelineChristopher P Fox, Matthew J Ahearne, Ruth Pettengell, et al.
British Journal of Haematology|January 4, 2012
Guidelines on the investigation and management of follicular lymphomaChristopher McNamara, John Davies, Martin Dyer, et al.
Pageof 7